Botanix Pharmaceuticals Limited stock analysis
Want to see AU:BOT full AI Analyst Report?
Botanix Pharmaceuticals Limited (BOT) Share Price & Analysis
BOT Stock Chart & Stats
- Day’s Range
- AUD 0.01 - AUD 0.01
- 52-Week Range
- AUD 0.01 - AUD 0.15
- Previous Close
- AUD 0.01
- Volume
- N/A
- Average Volume (3M)
- 9.48M
- Market Cap
- AUD 22.10M
- Enterprise Value
- AUD 34.48M
- Total Cash (Recent Filing)
- AUD 36.63M
- Total Debt (Recent Filing)
- AUD 14.74M
- Price to Earnings (P/E)
- ―
- Beta
- 1.04
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- -0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Rapid revenue growth indicates increasing commercial traction and expanding demand for the company’s offerings. If this momentum persists, it could improve operating leverage, support broader market adoption, and provide a stronger foundation for eventually funding development from internal resources.
Reduced Debt
Debt reduction alongside a meaningful equity base improves financial flexibility and lowers leverage-related pressure. This gives the company more capacity to manage its clinical and regulatory activities, although continued losses could still reduce the strength of that cushion over time.
Focused Dermatology Pipeline
A focused topical dermatology strategy can concentrate scientific, clinical, and regulatory resources on a defined set of skin-disease opportunities. Prescription products addressing recognized dermatologic conditions could create durable commercial potential if development and regulatory preparation succeed.
Bears Say
Persistent Unprofitability
Persistent operating and net losses show that revenue growth has not yet translated into an economically sustainable business model. Deeply negative gross profit also raises uncertainty around margin durability, leaving the company dependent on future improvement in commercial performance and cost absorption.
Heavy Cash Burn
Large recurring cash outflows reduce the company’s ability to fund operations and development internally. Until revenue and margins improve materially, continued cash burn implies reliance on external funding, which can constrain strategic flexibility and increase financing pressure over the next several quarters.
Declining Equity Cushion
A shrinking equity base indicates that ongoing losses are consuming shareholder capital despite the remaining balance-sheet cushion. Strongly negative returns on equity further demonstrate inefficient capital use, potentially limiting the resources available for sustained investment in the pipeline.
Botanix Pharmaceuticals Limited News
BOT FAQ
What was Botanix Pharmaceuticals Limited’s price range in the past 12 months?
What is Botanix Pharmaceuticals Limited’s market cap?
When is Botanix Pharmaceuticals Limited’s upcoming earnings report date?
How were Botanix Pharmaceuticals Limited’s earnings last quarter?
Is Botanix Pharmaceuticals Limited overvalued?
Does Botanix Pharmaceuticals Limited pay dividends?
What is Botanix Pharmaceuticals Limited’s EPS estimate?
How many shares outstanding does Botanix Pharmaceuticals Limited have?
What happened to Botanix Pharmaceuticals Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Botanix Pharmaceuticals Limited?
What is the TipRanks Smart Score and how is it calculated?
Botanix Pharmaceuticals Limited Stock Smart Score
Company Description
Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited, an Australian enterprise, is dedicated to the discovery and advancement of novel dermatological and antimicrobial therapeutic agents. The company's central mission involves pioneering innovative treatments for widespread skin conditions and various infections. Its robust developmental portfolio showcases several key assets: Sofpironium Bromide, which has successfully completed Phase 3 clinical studies for managing primary axillary hyperhidrosis; BTX 1503, a transdermal gel designed to tackle severe acne in both adults and teenagers, having concluded Phase II trials; BTX 1801, which has progressed through Phase IIb clinical investigations for infections caused by Staphylococcus aureus (including its methicillin-resistant variant); BTX 1702, currently undergoing Phase IIb clinical evaluation for papulopustular rosacea; and BTX 1204A, targeting atopic dermatitis. Established in 1984, Botanix Pharmaceuticals operates from its headquarters in Leederville, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Howie McKibbon
- Employees
- 11
- Website
- www.botanixpharma.com
- Address
- Tower 5, Collins Square, Melbourne, VIC, 3008, AU
Botanix Pharmaceuticals Limited (BOT) Earnings & Revenues
BOT Earnings Call
Earnings Call SentimentNeutral
The call conveyed strong commercial momentum — rapid prescription growth, meaningful revenue ramp, a high‑performing fulfillment platform (fill rates ~2.5x industry), positive physician adoption signals (90% expect to increase prescribing) and an attractive IP runway to 2040. Counterbalancing this progress are sizeable operating losses (adjusted EBITDA loss $26.1M; loss before tax $33.2M), material near‑term API purchase obligations and reliance on a partially‑completed capital raise and a single API supplier. Management has identified clear catalysts (alternate API supplier to cut COGS 25%–40%, platform scalability, and $45M committed raise) but execution and funding are key near‑term risks. Overall, the call was upbeat on commercial execution but sober about cash, supply and funding needs.
View all AU:BOT earnings summariesBOT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 13 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 1 | 0 | 11 |









